Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpeeDx Ciprofloxacin gyrA Assay for Neisseria Gonorrhea
NCT05286931Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ciprofloxacin in gonorrhea, sponsored by University of Washington. Primary endpoints: Number and proportion of Neisseria Gonorrhea cases that can be cured with ciprofloxacin at 2 years and Effectiveness of treating patients with Neisseria Gonorrhea gyrA wildtype with Ciprofloxacin at 2 years. Started Mar 2022; status: recruiting.
02
Drugs
ciprofloxacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT05286931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286931.